Nothing Special   »   [go: up one dir, main page]

Propson et al., 2021 - Google Patents

Complement in neurologic disease

Propson et al., 2021

Document ID
8342466001127111181
Author
Propson N
Gedam M
Zheng H
Publication year
Publication venue
Annual Review of Pathology: Mechanisms of Disease

External Links

Snippet

Classic innate immune signaling pathways provide most of the immune response in the brain. This response activates many of the canonical signaling mechanisms identified in peripheral immune cells, despite their relative absence in this immune-privileged tissue …
Continue reading at www.annualreviews.org (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic, hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Similar Documents

Publication Publication Date Title
Propson et al. Complement in neurologic disease
Nizami et al. Microglial inflammation and phagocytosis in Alzheimer's disease: potential therapeutic targets
Sokolowski et al. Phagocytic clearance in neurodegeneration
Painter et al. TREM2 in CNS homeostasis and neurodegenerative disease
Wes et al. Targeting microglia for the treatment of Alzheimer's Disease
Spangenberg et al. Inflammation in Alzheimer’s disease: lessons learned from microglia-depletion models
Druart et al. Emerging roles of complement in psychiatric disorders
Spangenberg et al. Eliminating microglia in Alzheimer’s mice prevents neuronal loss without modulating amyloid-β pathology
Wyss-Coray Inflammation in Alzheimer disease: driving force, bystander or beneficial response?
Audrain et al. Integrative approach to sporadic Alzheimer’s disease: deficiency of TYROBP in a tauopathy mouse model reduces C1q and normalizes clinical phenotype while increasing spread and state of phosphorylation of tau
Qin et al. Stimulation of TLR4 attenuates Alzheimer’s disease–related symptoms and pathology in tau-transgenic mice
Cortes et al. Rapamycin delays disease onset and prevents PrP plaque deposition in a mouse model of Gerstmann–Sträussler–Scheinker disease
Derecki et al. Microglia as a critical player in both developmental and late-life CNS pathologies
Zheng et al. Huntington disease and the huntingtin protein
Cacabelos Pharmacogenomics in Alzheimer's disease
Nielsen et al. Binding and uptake of Aβ1‐42 by primary human astrocytes in vitro
Estfanous et al. Elevated expression of MiR-17 in microglia of Alzheimer’s disease patients abrogates autophagy-mediated amyloid-β degradation
Hofmann et al. RNA binding proteins and the pathogenesis of frontotemporal lobar degeneration
Li et al. ApoE4 reduction: An emerging and promising therapeutic strategy for Alzheimer's disease
Cisbani et al. Targeting innate immunity to protect and cure Alzheimer’s disease: opportunities and pitfalls
Vasilevko et al. Aging and cerebrovascular dysfunction: contribution of hypertension, cerebral amyloid angiopathy, and immunotherapy
Oliveros et al. Repurposing ibudilast to mitigate Alzheimer’s disease by targeting inflammation
Patel et al. Upregulation of BDNF and hippocampal functions by a hippocampal ligand of PPARα
Agrawal et al. Comprehensive review of ASC structure and function in immune homeostasis and disease
Karam et al. Molecular mechanisms and therapeutic strategies in spinocerebellar ataxia type 7